Skip to NavigationSkip to content

Aduro Biotech

Top Ten most popular articles on this week!

The Institute for Cancer Research (ICR) called for new measures to increase the speed with which patients in the UK access innovative cancer drugs, this week. The institute suggested a new approach to funding models was necessary in order to encourage innovation.

The call came as Pfizer’s head of immune-oncology joined cancer focused firm Aduro Biotech as the company’s new CMO. The move may lead to new and innovative immunotherapies. Meanwhile GSK exec Richard Saynor was named as Novartis subsidiary Sandoz’ new CEO.

Pfizer immune-oncology leader joins Aduro Biotech as new CMO

Pfizer’s vice president and head of immune-oncology clinical development has joined Aduro Biotech as the company’s new Chief Medical Officer, just three months after the firm laid of more than a third of its workforce, as it refocused its efforts on developing treatments for cancer.

Weekly Movers: Valeant, Anacor, Regeneron…

Published on 23/05/16 at 09:12am

The earnings season came to a close with Germany’s Merck doubling its first-quarter profits. For the week, drug trials, analyst comments and deals were some of the drivers behind big share movements.

Here’s a quick look at some of the biggest movers of the week:

Shares in Valeant Pharmaceuticals (NYSE: VRX) rose almost 4% after it was revealed David Tepper's hedge-fund firm Appaloosa bought nearly 1 million shares in the company in the first three months of 2016.

Aduro's pancreatic cancer immunotherapy fails Phase II trials; shares plunge

Shares in Aduro Biotech (Nasdaq: ADRO) dropped to closed down over 16% after the company said mid-stage trials of its drug to treat pancreatic cancer failed to improve overall survival.

Pre-market trading in the shares was halted Monday following the news. Aduro's shares fell 33% in premarket trading.

In the study, patients were given either CRS-207 or chemotherapy or a combination of CRS-207 with Aduro's GVAX Pancreas, the company said.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches